In vitro studies using benzamide derivatives of olaparib, which have both PARP and HDAC inhibition activities, showed induction of BRCAness, promotion of cytosolic DNA accumulation, activation of the cGAS–STING pathway, induction of DNA damage, and production of proinflammatory chemokines through the JAK–STAT pathway in triple-negative breast cancer cell lines [37]. This evidence concerns the gene PARP1 and triple-negative breast carcinoma.